Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases

Immunotherapy in Lung Cancer

(2017) Lingling Du et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

PL04a.04: Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC

(2017) Julien Adam et al.   Journal of Thoracic Oncology

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases

(2017) Hironori Uruga et al.   Journal of Thoracic Oncology

Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy

(2017) Thomas J Gniadek et al.   MODERN PATHOLOGY

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

(2017) David L. Rimm et al.   JAMA Oncology

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2016) S. Novello et al.   ANNALS OF ONCOLOGY

Non–Small Cell Lung Cancer, PD-L1, and the Pathologist

(2016) Keith M. Kerr et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

(2016) Corey J. Langer et al.   Journal of Thoracic Oncology

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases

(2016) Jong-Mu Sun et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

(2016) Scott Antonia et al.   LANCET ONCOLOGY

Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer

(2016) Jamaal A Rehman et al.   MODERN PATHOLOGY

Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas

(2016) Andreas H Scheel et al.   MODERN PATHOLOGY

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed cell death ligand-1 (PD-L1) expression by immunohistochemistry: could it be predictive and/or prognostic in non-small cell lung cancer?

(2016) Mari Mino-Kenudson et al.   Cancer Biology & Medicine

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers

(2015) Moon-Young Kim et al.   LUNG CANCER

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation

(2014) Miguel F. Sanmamed et al.   CANCER JOURNAL

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC

(2014) Stéphane Champiat et al.   Journal of Thoracic Oncology

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

Next-generation tissue microarray (ngTMA) increases the quality of biomarker studies: an example using CD3, CD8, and CD45RO in the tumor microenvironment of six different solid tumor types

(2013) Inti Zlobec et al.   Journal of Translational Medicine

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration

(2012) Douglas G. Altman et al.   PLOS MEDICINE